Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$7.50
-0.49-6.13%
At close: -
$7.84
0.344.53%
After Hours: Jun 13, 6:22 PM EDT
Comments
Loading...
Seres Therapeutics Analyst Ratings and Price Targets | NASDAQ:MCRB | Benzinga
Seres Therapeutics Inc has a consensus price target of $10.46 based on the ratings of 8 analysts. The high is $25 issued by HC Wainwright & Co. on March 8, 2023. The low is $0.75 issued by Goldman Sachs on March 14, 2025. The 3 most-recent analyst ratings were released by Chardan Capital, Chardan Capital, and Goldman Sachs on May 8, 2025, March 20, 2025, and March 14, 2025, respectively. With an average price target of $2.67 between Chardan Capital, Chardan Capital, and Goldman Sachs, there's an implied -65.99% downside for Seres Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Chardan Capital
Goldman Sachs
Canaccord Genuity
Oppenheimer
HC Wainwright & Co.
1calculated from analyst ratings
Analyst Ratings for Seres Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/08/2025 | Buy Now | -23.47% | Chardan Capital | Keay Nakae56% | $1.25 → $6 | Downgrade | Buy → Neutral | Get Alert |
| 03/20/2025 | Buy Now | -84.06% | Chardan Capital | Keay Nakae56% | $1.25 → $1.25 | Maintains | Buy | Get Alert |
| 03/14/2025 | Buy Now | -90.43% | Goldman Sachs | Chris Shibutani56% | $1 → $0.75 | Maintains | Sell | Get Alert |
| 11/14/2024 | Buy Now | 27.55% | Canaccord Genuity | John Newman46% | $10 → $10 | Maintains | Buy | Get Alert |
| 11/13/2024 | Buy Now | -84.06% | Chardan Capital | Keay Nakae56% | $1.25 → $1.25 | Maintains | Buy | Get Alert |
| 10/24/2024 | Buy Now | — | JP Morgan | Tessa Romero62% | — | Downgrade | Neutral → Underweight | Get Alert |
| 09/13/2024 | Buy Now | 27.55% | Canaccord Genuity | John Newman46% | $10 → $10 | Maintains | Buy | Get Alert |
| 08/14/2024 | Buy Now | 27.55% | Canaccord Genuity | John Newman46% | $10 → $10 | Maintains | Buy | Get Alert |
| 08/14/2024 | Buy Now | -84.06% | Chardan Capital | Keay Nakae56% | $1.25 → $1.25 | Maintains | Buy | Get Alert |
| 06/07/2024 | Buy Now | — | Oppenheimer | Jeff Jones38% | — | Downgrade | Outperform → Perform | Get Alert |
| 06/07/2024 | Buy Now | 27.55% | Canaccord Genuity | John Newman46% | $15 → $10 | Maintains | Buy | Get Alert |
| 05/09/2024 | Buy Now | -48.98% | Oppenheimer | Jeff Jones38% | $5 → $4 | Maintains | Outperform | Get Alert |
| 05/08/2024 | Buy Now | -23.47% | Chardan Capital | Keay Nakae56% | $8 → $6 | Maintains | Buy | Get Alert |
| 03/06/2024 | Buy Now | -36.22% | Oppenheimer | Jeff Jones38% | $9 → $5 | Maintains | Outperform | Get Alert |
| 03/06/2024 | Buy Now | 2.04% | Chardan Capital | Keay Nakae56% | $10 → $8 | Maintains | Buy | Get Alert |
| 01/16/2024 | Buy Now | 14.8% | Oppenheimer | Jeff Jones38% | $10 → $9 | Maintains | Outperform | Get Alert |
| 11/03/2023 | Buy Now | -84.06% | Goldman Sachs | Chris Shibutani56% | $4 → $1.25 | Maintains | Sell | Get Alert |
| 06/26/2023 | Buy Now | 53.06% | Oppenheimer | Mark Breidenbach47% | → $12 | Assumes | → Outperform | Get Alert |
| 04/28/2023 | Buy Now | 27.55% | Chardan Capital | Keay Nakae56% | $12 → $10 | Maintains | Buy | Get Alert |
| 04/21/2023 | Buy Now | -10.71% | JP Morgan | Tessa Romero62% | → $7 | Initiates | → Neutral | Get Alert |
| 03/21/2023 | Buy Now | 91.33% | Canaccord Genuity | John Newman46% | $11 → $15 | Maintains | Buy | Get Alert |
| 03/08/2023 | Buy Now | 40.31% | Canaccord Genuity | John Newman46% | $17 → $11 | Maintains | Buy | Get Alert |
| 03/08/2023 | Buy Now | 53.06% | Chardan Capital | Keay Nakae56% | → $12 | Reiterates | → Buy | Get Alert |
| 03/08/2023 | Buy Now | 218.88% | HC Wainwright & Co. | Vernon Bernardino51% | → $25 | Reiterates | → Buy | Get Alert |
| 02/08/2023 | Buy Now | 218.88% | HC Wainwright & Co. | Vernon Bernardino51% | → $25 | Reiterates | → Buy | Get Alert |
| 09/07/2022 | Buy Now | 14.8% | Piper Sandler | Edward Tenthoff52% | $7 → $9 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Seres Therapeutics (MCRB) stock?
The latest price target for Seres Therapeutics (NASDAQ:MCRB) was reported by Chardan Capital on May 8, 2025. The analyst firm set a price target for $6.00 expecting MCRB to fall to within 12 months (a possible -23.47% downside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Seres Therapeutics (MCRB)?
The latest analyst rating for Seres Therapeutics (NASDAQ:MCRB) was provided by Chardan Capital, and Seres Therapeutics downgraded their neutral rating.
When was the last upgrade for Seres Therapeutics (MCRB)?
There is no last upgrade for Seres Therapeutics
When was the last downgrade for Seres Therapeutics (MCRB)?
The last downgrade for Seres Therapeutics Inc happened on May 8, 2025 when Chardan Capital changed their price target from $1.25 to $6 for Seres Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Seres Therapeutics (MCRB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Seres Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Seres Therapeutics was filed on May 8, 2025 so you should expect the next rating to be made available sometime around May 8, 2026.
Is the Analyst Rating Seres Therapeutics (MCRB) correct?
While ratings are subjective and will change, the latest Seres Therapeutics (MCRB) rating was a downgraded with a price target of $1.25 to $6.00. The current price Seres Therapeutics (MCRB) is trading at is $7.84, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
